Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
On Monday, Morgan Stanley (NYSE:MS) downgraded XPLR Infrastructure (NYSE:NEP) from Overweight to Underweight, significantly reducing the price target to $13.00 from the prior $22.00. Currently trading at $10.54, the stock has experienced a dramatic 60% decline over the past year, according to InvestingPro data. The revised outlook follows a period of notable decline for the company’s shares, which have fallen sharply following the conclusion of its strategic review.
The downgrade by Morgan Stanley was prompted by the results of XPLR’s strategic review, which concluded without providing a clear value proposition for equity investors. The review’s outcome, which included a full distribution cut and free cash flow deficit due to capital expenditures and obligations, has increased uncertainty regarding the company’s future growth and strategy. InvestingPro analysis shows the company’s overall financial health score as "FAIR," with particularly concerning metrics in profitability and price momentum.
The strategic review’s conclusion led to a 25% drop in XPLR’s stock price once the news was released, followed by an additional 11% decrease through the rest of the week. Morgan Stanley had previously upgraded the stock on December 2, with the anticipation that the market had overly discounted potential negative outcomes. However, the review failed to meet expectations, resulting in a significant negative impact on the stock’s performance.
The analyst at Morgan Stanley noted that while their model revisions indicate some upside to the current stock price, the lack of a specific capital allocation framework and growth guidance for XPLR has created substantial doubts about the company’s long-term prospects. The uncertainty around these factors has made the firm cautious about relying on run-off value to establish a floor for the stock price.
In summary, Morgan Stanley’s downgrade reflects concerns about XPLR Infrastructure’s ability to articulate a compelling vision for equity investors, and the unresolved issues stemming from its strategic review have cast a shadow over the company’s outlook. While analyst targets range from $7 to $22, InvestingPro subscribers have access to detailed Fair Value analysis and 8 additional key insights about the company’s financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.